The European Commission Has Approved GSK's Respiratory Syncytial Virus Vaccine For Active Immunization For The Prevention Of Lower Respiratory Tract Disease Caused By A Respiratory Syncytial Virus In Adults 60 Years Of Age And Older
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved GSK's Respiratory Syncytial Virus (RSV) vaccine for active immunization in adults aged 60 and older. This marks the first RSV vaccine for older adults to receive European Marketing Authorisation, with launches planned ahead of the 2023/2024 RSV season.
June 07, 2023 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's RSV vaccine for adults aged 60 and older has been approved by the European Commission, marking a significant milestone for the company.
The approval of GSK's RSV vaccine by the European Commission is a significant milestone for the company, as it is the first RSV vaccine for older adults to receive European Marketing Authorisation. This approval will likely lead to increased demand for the vaccine and potential revenue growth for GSK, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100